This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2024
ASCO 2024 Bladder Cancer
Conferences
ASCO 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Upper Tract Urothelial Carcinoma
Press Releases
ASCO 2024 Bladder Cancer
Viewing 1-20 of 344 articles
AUA 2018: Inferior Vena Cava Level II Tumor Thrombectomy: Which is Best: Robot or Open?
AUA 2017: Trends in surgical approach and outcomes for radical cystectomy: a contemporary population-based analysis
AUA 2017: Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer
AUA 2017: Bladder cancers are not all the same: de novo muscle invasive disease has improved survival compared to invasive disease progressing after intravesical therapy
AUA 2017: Comparison of total 90 day costs for open versus robotic cystectomy
AUA 2017: Venous thromboembolism rates following radical cystectomy stratified by method of prophylaxis
AUA 2017: Restrictive transfusion in radical cystectomy is safe
AUA 2017: The prognostic value of postoperative clinical and laboratory parameters regarding the oncological outcome of patients undergoing radical cystectomy for urothelial cell carcinoma of the bladder
AUA 2017: Does sarcopenia impact oncologic outcomes in patients undergoing adjuvant chemotherapy following radical cystectomy?
AUA 2017: Late-Breaking Abstract – Interim results from a single-arm multicenter Phase II trial of CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)
AUA 2017: Late-Breaking Abstract – Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 expressing bladder cancer using combination photoimmunotherapy (PIT)
AUA 2017: Late-Breaking abstract- A phase III blinded study of immediate post-TURBT instillation of gemcitabine versus saline in patients with newly diagnosed or occasionally recurring Grade I/II non-muscle invasive bladder cancer: SWOG S0337
AUA 2017: Best Abstract – Are the current follow-up guidelines after treatment for organ confined renal cancer sufficient?
AUA 2017: Best Abstract – Liquid biopsy for renal cell carcinoma
AUA 2017: A molecular scoring algorithm to predict survival in metastatic renal cell carcinoma
AUA 2017: Thromboembolic events during treatment for renal cell carcinoma: must we prevent?
AUA 2017: Can looks deceive? Not all clinically “cystic” renal masses harbor indolent biology
AUA 2017: Differential gene expression in patients with indolent versus aggressive chromophobe renal cell carcinoma: An analysis of the cancer genome atlas database
AUA 2017: A prospective study on the impact of radical cystectomy on sexual function in females with bladder cancer
AUA 2017: National surgical quality improvement program surgical risk calculator poorly predicts complications in patients undergoing radical cystectomy with urinary diversion: the case for a procedure-specific risk calculator
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free